Abstract | OBJECTIVE: MATERIALS AND METHODS: Research searching was performed in PubMed and EMBASE databases and the Cochrane library in May 2018. Clinical controlled trials using pregabalin for the pain treatment following SCI in adults (18 y old and above) were included. Pain and safety-related adverse events were considered as outcomes. Meta-analysis was conducted using Revman 5.0 software. RESULTS: Five publications ( pregabalin, patients=261, placebo, patients=216) were included in our study. After at least 4-week's treatment with pregabalin (flexible dose, 150 to 600 mg/d), pregabalin-treated patients showed reduced pain -1.54, 95% confidence interval (CI) (-2.33, -0.75), P=0.0001; improved >30% 1.83, 95% CI (1.37, 2.46), P<0.0001 and >50% pain relief 2.40, 95% CI (1.53, 3.77), P=0.0001; increased adverse events 1.36, 95% CI (1.18, 1.577), P<0.0001; and reduced Hospital Anxiety and Depression Scale - anxiety -1.50, 95% CI (-2.99, -0.00), P=0.05 and - depression -0.34, 95% CI (-0.55, -0.12), P=0.002 scores compared with placebo-treated patients. Stratified meta-analysis showed there was no difference in primary adverse events (drowsiness, dizziness, peripheral edema, and dry mouth) between pregabalin and placebo groups (P≥0.05). CONCLUSIONS:
|
Authors | Xiaobing Yu, Tao Liu, Dewei Zhao, Ke Yang, Xiuzhi Zhang, Meng Zhang, Shuo Zhang, Wei Huang, Baolin Wu, Junlei Li |
Journal | The Clinical journal of pain
(Clin J Pain)
Vol. 35
Issue 3
Pg. 272-278
(03 2019)
ISSN: 1536-5409 [Electronic] United States |
PMID | 30499836
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
|
Topics |
- Analgesics
(adverse effects, therapeutic use)
- Chronic Pain
(drug therapy, etiology)
- Humans
- Neuralgia
(drug therapy, etiology)
- Pregabalin
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Spinal Cord Injuries
(complications)
|